Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis
British Journal of Haematology, 08/21/2012
Clinical Article
Lee L et al. – The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improves survival in the general population of patients with diffuse large B–cell lymphoma (DLBCL) and produces early survival benefit for very elderly patients, without any significant increase in the risk of serious toxicity.
